Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion type Assertion NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_head.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion description "[Therefore, SHIP2 remains a significant therapeutic target for the treatment of both obesity and type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_provenance.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion evidence source_evidence_literature NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_provenance.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion SIO_000772 15964236 NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_provenance.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion wasDerivedFrom befree-20150227 NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_provenance.
- NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_assertion wasGeneratedBy ECO_0000203 NP513373.RAAhuN8SApbL4wMgI3wv4QklUePxtufHBTE3vrMHp58L4130_provenance.